Olverembatinib
-
With global innovation map further expanded, Ascentage Pharma saw a 477% surge in revenue in the first half of 2024
The development of original new drugs has always been considered a high-risk industry. A d…
-
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Congratulations! This is the latest cross-border licensing out deal by a pharma/biotech in China
